Precision Biosciences (DTIL) Long-Term Investments (2021 - 2026)
Precision Biosciences (DTIL) posted quarterly Long-Term Investments of $744000.0 for Q1 2026, down 76.79% year-over-year from $3.2 million in Q1 2025, and little changed quarter-over-quarter from $744000.0 in Q4 2025.
Precision Biosciences (DTIL) Long-Term Investments (2021 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Long-Term Investments for 6 consecutive years, with $744000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Long-Term Investments fell 76.79% year-over-year to $744000.0; the TTM figure through Mar 2026 stood at $744000.0 (down 76.79% YoY), while the FY2025 annual figure was $744000.0, down 76.79% from the prior year.
- Long-Term Investments steadied at $744000.0 in Q1 2026 per DTIL's latest filing, from $744000.0 in the prior quarter.
- Across five years, Long-Term Investments topped out at $3.2 million in Q4 2023 and bottomed at $744000.0 in Q2 2025.
- Historically, Long-Term Investments has averaged $2.3 million across 5 years, with a median of $3.1 million in 2022.
- Annual changes were most pronounced in 2022 — Long-Term Investments surged 280.67% — and 2025, when it sank 76.79%.
- Precision Biosciences' Long-Term Investments stood at $2.6 million in 2022, then increased by 24.46% to $3.2 million in 2023, then changed by 0.0% to $3.2 million in 2024, then tumbled by 76.79% to $744000.0 in 2025, then changed by 0.0% to $744000.0 in 2026.
- Business Quant data shows DTIL's Long-Term Investments at $744000.0 in Q1 2026, $744000.0 in Q4 2025, and $744000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - | 744,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 744,000.00 |
| Mar 31, 2026 | 744,000.00 |
| Dec 31, 2025 | 744,000.00 |
| Sep 30, 2025 | 744,000.00 |
| Jun 30, 2025 | 744,000.00 |
| Mar 31, 2025 | 3.21 Mn |
| Dec 31, 2024 | 3.21 Mn |
| Sep 30, 2024 | 3.21 Mn |
| Jun 30, 2024 | 3.21 Mn |
| Mar 31, 2024 | 3.21 Mn |
| Dec 31, 2023 | 3.21 Mn |
| Sep 30, 2023 | 1.81 Mn |
| Jun 30, 2023 | 1.81 Mn |
| Mar 31, 2023 | 1.81 Mn |
| Dec 31, 2022 | 2.58 Mn |
| Sep 30, 2022 | 3.09 Mn |
| Jun 30, 2022 | 3.09 Mn |
| Mar 31, 2022 | 3.09 Mn |
| Dec 31, 2021 | 3.75 Mn |
| Sep 30, 2021 | 812,000.00 |